To include your compound in the COVID-19 Resource Center, submit it here.

Non-toxigenic Clostridium difficile: Phase II started

ViroPharma began a double-blind, placebo-controlled, dose-ranging, international Phase II trial to

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE